Top

Published in:

Open Access 01-12-2012 | Research

Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer

Authors: Mehmet Eser, Metin Kement, Salim Balin, Cihan Coskun, Umut Kefeli, Mahmut Gumus, Yunus Emre Altuntas, Necmi Kurt, Alparslan Mayadagli

Published in: World Journal of Surgical Oncology | Issue 1/2012

Abstract

Background

The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients.

Methods

Thirty-three patients with gastric adenocarcinoma and 29 healthy control subjects were prospectively enrolled in the study. Patients who had a history of secondary malignancy, thrombosis related disease, oral contraceptive use, diabetes mellitus, chronic renal failure or similar chronic metabolic disease were excluded from the study. A fasting blood sample was drawn from patients to determine the plasma levels of TAFI and Prothrombin Fragment 1 + 2 (F 1 + 2). In addition, data on patient age, sex, body mass index (BMI) and stage of disease were recorded. The same parameters, except stage of disease, were also recorded for the control group. Subsequently, we assessed the difference in the levels of TAFI and F 1 + 2 between the patient and control groups. Moreover, we investigated the relation of TAFI and F 1 + 2 levels with age, sex, BMI and stage of disease in the gastric cancer group.

Results

There were no statistical differences in any demographic variables (age, gender and BMI) between the groups (Table 1). The mean plasma TAFI levels of the gastric cancer group (69.4 ± 33.1) and control group (73.3 ± 27.5) were statistically similar (P = 0.62). The mean plasma F 1 + 2 level in the gastric cancer group was significantly higher than for those in the control group (549.7 ± 325.3 vs 151.9 ± 67.1, respectively; P < 0.001). In the gastric cancer group, none of the demographic variables (age, gender and BMI) were correlated with either TAFI or F 1 + 2 levels. Also, no significant associations were found between the stage of the cancer and either TAFI or F 1 + 2 levels.

Conclusion

In our study, TAFI levels of gastric cancer patients were similar to healthy subjects. The results of our study suggest that TAFI does not play a role in pathogenesis of the hypercoagulable state in gastric cancer patients.

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007, 5: 632-634. 10.1111/j.1538-7836.2007.02374.x.CrossRefPubMed

Blom JW, Doggen CJ, Osanto S, Rosendaal FR: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005, 293: 715-722. 10.1001/jama.293.6.715.CrossRefPubMed

Khorana AA, Connolly GC: Assessing risk of venous thromboembolism in the cancer patient. J Clin Oncol. 2009, 27: 4839-4847. 10.1200/JCO.2009.22.3271.PubMedCentralCrossRefPubMed

Sousou T, Khorana A: Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie. 2009, 29: 121-124.PubMed

Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulators of theplasminogen system. J Clin Invest. 1995, 96: 2534-2538. 10.1172/JCI118315.PubMedCentralCrossRefPubMed

Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995, 270: 14477-14484. 10.1074/jbc.270.24.14477.CrossRefPubMed

Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996, 271: 16603-16608. 10.1074/jbc.271.28.16603.CrossRefPubMed

Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME: A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998, 273: 27176-27181. 10.1074/jbc.273.42.27176.CrossRefPubMed

Hendriks D, Wang W, Scharpé S, Lommaert MP, van Sande M: Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta. 1990, 1034: 86-92. 10.1016/0304-4165(90)90157-R.CrossRefPubMed

10.

Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD: Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004, 2: 2107-2114. 10.1111/j.1538-7836.2004.01011.x.CrossRefPubMed

11.

Marx PF, Dawson PE, Bouma BN, Meijers JC: Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry. 2002, 41: 6688-6696. 10.1021/bi015982e.CrossRefPubMed

12.

Boffa MB, Hamill JD, Bastajian N, Dillon R, Nesheim ME, Koschinsky ML: A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem. 2002, 277: 25329-25336. 10.1074/jbc.M203688200.CrossRefPubMed

13.

Fujimoto H, Gabazza EC, Taguchi O, Yuda Y, Hataji O, Adachi Y: Increased intraalveolar levels of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease. Am J Respir Crit Care Med. 2003, 167: 1687-1694. 10.1164/rccm.200208-905OC.CrossRefPubMed

14.

Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y: Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab. 2002, 87: 660-665. 10.1210/jc.87.2.660.CrossRefPubMed

15.

Hulme JP, An SSA: Detecting activated thrombin activatable fibrinolysis inhibitor (TAFIa) and inactivated TAFIa (TAFIai) in normal and hemophilia a plasma. Bull Korean Chem Soc. 2009, 30: 77-82.CrossRef

16.

van Tilburg NH, Rosendaal FR, Bertina RM: Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000, 95: 2855-2859.PubMed

17.

Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A: Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000, 84: 364-368.PubMed

18.

Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H: Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res. 2001, 104: 1-6. 10.1016/S0049-3848(01)00331-0.CrossRefPubMed

19.

Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995, 345: 152-155. 10.1016/S0140-6736(95)90166-3.CrossRefPubMed

20.

Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR: High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000, 342: 696-701. 10.1056/NEJM200003093421004.CrossRefPubMed

21.

Hataji O, Taguchi O, Gabazza EC, Yuda H, D’Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y: Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol. 2004, 76: 214-219. 10.1002/ajh.20079.CrossRefPubMed

22.

Balcik OS, Albayrak M, Uyar ME, Dagdas S, Yokus O, Ceran F, Cipil H, Kosar A, Ozet G: Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma. Blood Coagul Fibrinolysis. 2011, 22: 260-263. 10.1097/MBC.0b013e3283442cf9.CrossRefPubMed

23.

Kaftan O, Kasapoglu B, Koroglu M, Kosar A, Yalcin SK: Thrombin-activatable fibrinolysis inhibitor in breast cancer patients. Med Princ Pract. 2011, 20: 332-335. 10.1159/000324547.CrossRefPubMed

24.

Zacharski LR: Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. 2002, 186: 1-9. 10.1016/S0304-3835(02)00258-6.CrossRefPubMed

25.

Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I: D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009, 27: 4124-4129. 10.1200/JCO.2008.21.7752.CrossRefPubMed

26.

Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F: Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer. Tumour Biol. 2012, Epub ahead of print

Title: Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
Authors: Mehmet Eser
Metin Kement
Salim Balin
Cihan Coskun
Umut Kefeli
Mahmut Gumus
Yunus Emre Altuntas
Necmi Kurt
Alparslan Mayadagli
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-10-180

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma

A rare giant gastrointestinal stromal tumor of the stomach traversing the upper abdomen: a case report and literature review

Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

Three uncommon adrenal incidentalomas: a 13-year surgical pathology review

Myxofibrosarcoma of the sinus piriformis: case report and literature review